Thursday 25th, well it wil be interesting. CU6 probably a better guide to gauge an idea rather than TLX in terms of progression but when you look at market caps/EV there is plenty of room for RAD to move. Management is impressive with the recent new appointment Riccardo Canevari to be CEO who came from Novartis. From a recent article:
There has been an extreme level of investor interest in the radiopharmaceutical sector in recent years and significant M&A activity globally including within the key market of China. Several key transactions have led to this activity including the Novartis acquisition of Advanced Accelerator Applications and Endocyte for $3.9 billion and $2.1 billion respectively.
